Phibro Animal Health (NASDAQ:PAHC) Hits New 12-Month High Following Better-Than-Expected Earnings

Phibro Animal Health Corporation (NASDAQ:PAHC) hit a new 52-week high during mid-day trading on Thursday following a stronger than expected earnings report. The stock traded as high as $48.66 and last traded at $47.4450, with a volume of 139415 shares changing hands. The stock had previously closed at $41.00.

The company reported $0.87 EPS for the quarter, topping analysts’ consensus estimates of $0.69 by $0.18. Phibro Animal Health had a net margin of 4.85% and a return on equity of 36.26%. The firm had revenue of $373.91 million for the quarter, compared to the consensus estimate of $355.64 million. Phibro Animal Health has set its FY 2026 guidance at 2.930-3.100 EPS.

Phibro Animal Health Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, March 25th. Shareholders of record on Wednesday, March 4th will be given a dividend of $0.12 per share. This represents a $0.48 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date is Wednesday, March 4th. Phibro Animal Health’s payout ratio is presently 28.92%.

Trending Headlines about Phibro Animal Health

Here are the key news stories impacting Phibro Animal Health this week:

• Positive Sentiment: Q2 results beat expectations — Phibro reported $0.87 EPS vs. $0.69 consensus and revenue of $373.9M (>$355.6M consensus); net income and sales rose year-over-year, giving a clear fundamental lift. Phibro Animal Health Corporation Reports Second Quarter Results, Updates Financial Guidance
• Positive Sentiment: Company raised FY2026 EPS guidance to $2.93–$3.10 (above the ~$2.75 consensus), signaling stronger full‑year profitability expectations — a material reason investors bid up the stock. Phibro Animal Health Corporation Reports Second Quarter Results, Updates Financial Guidance
• Positive Sentiment: Market reaction — some outlets noted the stock jumped (MSN: “soars 5.5%”) despite mixed headlines, reflecting that investors favored the EPS beat and raised guidance over any revenue/messaging noise. Phibro Animal Health (NASDAQ:PAHC) misses Q2 CY2026 revenue estimates, but stock soars 5.5%
• Positive Sentiment: Dividend announced — board declared a $0.12 quarterly cash dividend (payable March 25), which supports yield-focused investors and can be a modest positive for sentiment. Phibro Animal Health Corporation Declares Quarterly Dividend
• Neutral Sentiment: Company provided slide deck and press materials for the quarter — useful for investors doing deeper diligence but neutral on immediate price direction. Q2 Slide Deck
• Negative Sentiment: Analyst/coverage noise — a recent article flagged a “pessimistic outlook” from Zacks on Q2 expectations, which can create short-term selling pressure or uncertainty for some investors. Zacks Research Has Pessimistic Outlook of PAHC Q2 Earnings
• Negative Sentiment: Insider selling — filings show Jack Bendheim sold roughly 6.7K shares in recent transactions; while not huge relative to market cap, insider sales can be viewed negatively by some traders. Jack Bendheim Sells 6,693 Shares of Phibro Animal Health (NASDAQ:PAHC) Stock Jack Bendheim Sells 6,772 Shares of Phibro Animal Health (NASDAQ:PAHC) Stock

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the stock. Weiss Ratings reissued a “buy (b-)” rating on shares of Phibro Animal Health in a research note on Monday, December 29th. JPMorgan Chase & Co. raised their price objective on shares of Phibro Animal Health from $45.00 to $50.00 and gave the stock an “overweight” rating in a research note on Friday, November 7th. Finally, Zacks Research raised Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, December 9th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, two have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $31.40.

Insider Buying and Selling

In related news, CEO Jack Bendheim sold 38,303 shares of the stock in a transaction dated Monday, November 10th. The stock was sold at an average price of $45.29, for a total transaction of $1,734,742.87. Following the transaction, the chief executive officer directly owned 20,577 shares in the company, valued at approximately $931,932.33. This represents a 65.05% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders sold 161,060 shares of company stock valued at $6,945,844 in the last ninety days. Corporate insiders own 50.13% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Farther Finance Advisors LLC grew its holdings in Phibro Animal Health by 113.2% in the fourth quarter. Farther Finance Advisors LLC now owns 727 shares of the company’s stock valued at $27,000 after purchasing an additional 386 shares during the period. Hughes Financial Services LLC acquired a new position in shares of Phibro Animal Health in the 3rd quarter valued at $40,000. iSAM Funds UK Ltd purchased a new stake in shares of Phibro Animal Health during the 3rd quarter valued at $61,000. Advisory Services Network LLC acquired a new stake in shares of Phibro Animal Health during the 3rd quarter worth $96,000. Finally, EverSource Wealth Advisors LLC raised its position in shares of Phibro Animal Health by 7,671.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,720 shares of the company’s stock worth $69,000 after buying an additional 2,685 shares during the period. Institutional investors and hedge funds own 99.34% of the company’s stock.

Phibro Animal Health Stock Up 17.1%

The stock has a market cap of $1.95 billion, a price-to-earnings ratio of 28.92, a PEG ratio of 1.17 and a beta of 0.80. The company has a quick ratio of 1.35, a current ratio of 3.09 and a debt-to-equity ratio of 2.32. The stock has a fifty day moving average of $39.74 and a two-hundred day moving average of $38.06.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.